Larimar Therapeutics
increases in levels in phase trial cohort | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
12 of 44
Similar slides by Larimar Therapeutics
See diffirences between slides (animation)
Investor Presentation
November 2023
increases in levels observed in buccal cells cohort | Larimar Therapeutics
Investor Presentation
November 2023
increases in levels observed in skin cells cohort | Larimar Therapeutics
Investor Presentation
November 2023
dose dependent increases in levels observed in skin and buccal cells in phase | Larimar Therapeutics
Investor Presentation
November 2023
dose dependent increases in levels observed in skin and buccal cells in phase | Larimar Therapeutics
Related slides by other companies
9 Meters Biopharma
Investor Presentation
September 2022
relative change from placebo | 9 Meters Biopharma
Old Second Bancorp
Investor Conference
May 2023
transformation with higher interest rates me | Old Second Bancorp
PaxMedica
Investor Presentation
October 2022
secondary clinical global impression of improvement in overall severity of symptoms change from | PaxMedica
AN2 Therapeutics
Investor Presentation
February 2025
clinical achieved across two pros in to treat patients | AN2 Therapeutics
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights